S. Nanjo

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

This study identifies a FAK-YAP signaling axis that drives drug-tolerant persister cells and residual disease in lung cancer, showing that inhibiting this axis improves tumor response to targeted therapies.

Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts

The paper uses single-cell lineage tracing and RNA-seq to identify diverse metastatic behaviors and their drivers in lung cancer xenografts in mice.

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

This study shows that targeted cancer therapy induces APOBEC-mediated mutagenesis, promoting drug resistance by increasing genetic diversity through mechanisms involving NF-κB activation and reduced DNA repair.

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

This study shows that RBM10 deficiency reduces EGFR inhibitor efficacy in EGFR mutant lung cancer by altering Bcl-x splicing and apoptosis, and that co-inhibiting Bcl-xL can overcome this resistance.

A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer

The paper constructs a tyrosine kinase protein interaction map, revealing EGFR network oncogenesis in 19% of EGFR wild-type lung cancers, which is targetable with EGFR inhibitors.

The CIC-DUX4 fusion oncoprotein drives metastasis and tumor growth via distinct downstream regulatory programs and therapeutic targets in sarcoma

This study identifies ETV4 and CCNE1 as targets of the CIC-DUX4 fusion oncoprotein, showing their roles in sarcoma metastasis and tumor growth, and highlights therapeutic strategies targeting the CCNE-CDK2 complex.